Patents by Inventor Alberta Leon

Alberta Leon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury
    Patent number: 6620793
    Abstract: The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM1. Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM1 and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: September 16, 2003
    Assignee: Fidia Farmaceutici S.p.A.
    Inventors: Gino Toffano, Alberta Leon, Marino Massarotti
  • Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury
    Publication number: 20030153517
    Abstract: The invention relates to a method for amelioration of neurological outcome in humans with spinal cord damage by administration of ganglioside GM1. Another object of the present invention is to provide combination therapies for the treatment of spinal cord damage comprised of the administration of the ganglioside GM1 and other drugs which have therapeutical benefit in patients with spinal cord damage, preferably methylprednisolone.
    Type: Application
    Filed: April 18, 2002
    Publication date: August 14, 2003
    Applicant: Fidia, S.p.A.
    Inventors: Gino Toffano, Alberta Leon, Marino Massarotti
  • Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
    Patent number: 5990170
    Abstract: The following description concerns a therapeutic method for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, comprising administering amidic derivatives of mono and bicarboxylic acids with aminoalcohols or arninoethers selectively active on said receptor.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: November 23, 1999
    Assignee: Lifegroup S.p.A.
    Inventors: Francesco Della Valle, Alberta Leon, Gabriele Marcolongo, Silvana Lorenzi
  • Use of N-acyl derivatives of aminoalcohols in the manufacture of a medicament for practicing neuroprotective action in neuropathological states connected with excitotoxicity
    Patent number: 5925678
    Abstract: The use of N-acyl derivatives of aminoalcohols with mono- and di-carboxylic acids for the prevention and treatment of diseases connected with hyper and prolonged excitation by excitatory amino acids is described.
    Type: Grant
    Filed: September 23, 1996
    Date of Patent: July 20, 1999
    Assignee: Lifegroup S.P.A.
    Inventors: Francesco Della Valle, Alberta Leon, Silvana Lorenzi
  • Ganglioside derivatives
    Patent number: 5350841
    Abstract: Novel ganglioside derivatives comprised of a basic natural or semisynthetic ganglioside, in which the carboxyl group in the sialic part of the natural or semisynthetic ganglioside is converted into a carboxylamide with an aliphatic amino acid with a carboxylic or sulfonic acid function, and salts thereof are prepared. The semisynthetic ganglioside components can be chosen from the group consisting of N-acyl-N-lyso-gangliosides, N'-acyl-N'-lyso-gangliosides and N,N'-diacyl-N,N'-di-lyso-gangliosides, wherein "acyl" designates a moiety of an optionally substituted aliphatic acid. The ganglioside derivatives can be used in pharmaceutical preparations to be used in nervous system pathologies.
    Type: Grant
    Filed: July 31, 1992
    Date of Patent: September 27, 1994
    Assignee: Fidia S.p.A.
    Inventors: Aurelio Romeo, Gino Toffano, Alberta Leon